Checkpoint Therapeutics (CKPT) Competitors

Janux Therapeutics (NASDAQ:JANX) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings, valuation and community ranking.

Does the media favor JANX or CKPT?

In the previous week, Janux Therapeutics had 9 more articles in the media than Checkpoint Therapeutics. MarketBeat recorded 10 mentions for Janux Therapeutics and 1 mentions for Checkpoint Therapeutics. Checkpoint Therapeutics' average media sentiment score of 1.87 beat Janux Therapeutics' score of 1.13 indicating that Checkpoint Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Janux Therapeutics	Positive
Checkpoint Therapeutics	Very Positive

Which has more volatility and risk, JANX or CKPT?

Janux Therapeutics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.

Is JANX or CKPT more profitable?

Checkpoint Therapeutics has a net margin of 0.00% compared to Janux Therapeutics' net margin of -463.91%. Checkpoint Therapeutics' return on equity of 0.00% beat Janux Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	-463.91%	-10.47%	-9.86%
Checkpoint Therapeutics	N/A	N/A	-659.07%

Which has stronger valuation and earnings, JANX or CKPT?

Checkpoint Therapeutics has lower revenue, but higher earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$9.34M	162.14	-$58.29M	-$1.36	-18.81
Checkpoint Therapeutics	$41K	9,041.59	-$51.85M	-$1.29	-3.30

Do insiders & institutionals believe in JANX or CKPT?

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 22.0% of Checkpoint Therapeutics shares are owned by institutional investors. 8.1% of Janux Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Checkpoint Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Do analysts rate JANX or CKPT?

Janux Therapeutics currently has a consensus price target of $95.25, indicating a potential upside of 272.36%. Checkpoint Therapeutics has a consensus price target of $4.33, indicating a potential upside of 1.72%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Janux Therapeutics is more favorable than Checkpoint Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.09
Checkpoint Therapeutics	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Does the MarketBeat Community favor JANX or CKPT?

Checkpoint Therapeutics received 138 more outperform votes than Janux Therapeutics when rated by MarketBeat users. However, 70.97% of users gave Janux Therapeutics an outperform vote while only 67.16% of users gave Checkpoint Therapeutics an outperform vote.

Company	Underperform	Outperform
Janux Therapeutics	Outperform Votes 44 70.97%	Underperform Votes 18 29.03%
Checkpoint Therapeutics	Outperform Votes 182 67.16%	Underperform Votes 89 32.84%

Summary

Janux Therapeutics beats Checkpoint Therapeutics on 11 of the 19 factors compared between the two stocks.